Pfizer’s presence at ASCO 2024
Regimen produced clinically meaningful improvement in overall survival for certain patients with relapsed/refractory diffuse large b-cell lymphoma (DLBCL).
Find Out MoreTakeda and Pfizer announce positive four-year results from Phase 3 HD21 trial of combination treatment regimen in frontline classical Hodgkin lymphoma.
Find Out MoreFive year follow-up data shows prolonged progression-free survival in ALK-positive advanced lung cancer.
Find Out MoreBackground information about a rare, aggressive form of lung cancer called ALK-positive non-small cell lung cancer.
Find Out MoreAdvances in scientific research have brought new hope for patients with a rare, aggressive form of lung cancer.
Find Out MorePfizer is showcasing new research across the company’s key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates and bispecific antibodies.
Find Out MoreMore than 50 abstracts will be presented from Pfizer’s broadened portfolio of approved and pipeline therapies.
See Our Abstract ListTo help non-scientists better understand the latest research, we are providing abstract plain language summaries for key data at ASCO.
Find Out MorePfizer leaders share progress toward our vision: a world where people with cancer live better and longer lives.
Find Out MorePress Releases
All Pfizer published press releases by date and/or category of news
-
06.23.2022 Financial Investments Vaccines Valneva and Pfizer Announce Closing of Equity Investment -
06.23.2022 Financial Finance Pfizer Declares Third-Quarter 2022 Dividend -
06.20.2022 Vaccines Vaccines Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15 -
06.17.2022 Vaccines Covid-19 Vaccines Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age -
06.17.2022 Research and Pipeline Research Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain -
06.14.2022 Prescription Medicines Medicines Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug Application Submission to U.S. FDA -
06.09.2022 Financial Investments Pfizer Completes Acquisition of ReViral -
06.09.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference -
06.08.2022 Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference -
06.06.2022 Financial Covid-19 Investments Vaccines Pfizer to Invest $120 Million to Produce COVID-19 Oral Treatment in the U.S. -
06.04.2022 Prescription Medicines Medicines Pfizer Announces Overall Survival Results from Phase 3 PALOMA-2 Trial of IBRANCE® (palbociclib) for the First-Line Treatment of ER+, HER2- Metastatic Breast Cancer -
06.02.2022 Medicines Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Trust in Technology – A Snapshot
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind. Our findings underscored that patients won’t feel the full benefits of that technology if we don’t have trusted people – specifically health care providers – delivering it. We must partner with patients, healthcare providers, policy makers and others in the life sciences and tech industries to build trust in the technologies that are fueling the future of health.
Media Asset Library
A collection of assets for use by media.
Partnering News
The latest news from Pfizer and its strategic partners
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.